Parallel Advisors LLC Sells 773 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Parallel Advisors LLC lowered its position in shares of 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,601 shares of the company’s stock after selling 773 shares during the period. Parallel Advisors LLC’s holdings in 10x Genomics were worth $929,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Primecap Management Co. CA boosted its holdings in shares of 10x Genomics by 4.3% in the fourth quarter. Primecap Management Co. CA now owns 31,400 shares of the company’s stock worth $1,757,000 after buying an additional 1,300 shares during the last quarter. US Bancorp DE grew its position in shares of 10x Genomics by 19.4% during the 4th quarter. US Bancorp DE now owns 15,212 shares of the company’s stock valued at $851,000 after acquiring an additional 2,469 shares during the period. Balentine LLC purchased a new stake in shares of 10x Genomics in the 4th quarter worth $291,000. Dynamic Technology Lab Private Ltd bought a new position in 10x Genomics in the 4th quarter worth $596,000. Finally, Norges Bank purchased a new position in 10x Genomics during the fourth quarter valued at $36,262,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on TXG shares. Canaccord Genuity Group dropped their price objective on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 29th. Barclays reduced their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft cut their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. UBS Group decreased their price target on 10x Genomics from $52.00 to $30.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Finally, Bank of America cut their price objective on 10x Genomics from $45.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

View Our Latest Research Report on 10x Genomics

Insiders Place Their Bets

In other 10x Genomics news, CFO Justin J. Mcanear sold 2,936 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $71,344.80. Following the sale, the chief financial officer now directly owns 146,203 shares of the company’s stock, valued at approximately $3,552,732.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Justin J. Mcanear sold 2,936 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $71,344.80. Following the sale, the chief financial officer now directly owns 146,203 shares of the company’s stock, valued at $3,552,732.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 4,877 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the transaction, the chief executive officer now owns 889,641 shares of the company’s stock, valued at approximately $21,618,276.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,560 shares of company stock valued at $494,210. 10.03% of the stock is owned by insiders.

10x Genomics Price Performance

NASDAQ:TXG opened at $22.41 on Friday. The firm has a 50 day moving average of $29.55 and a 200 day moving average of $40.36. 10x Genomics, Inc. has a 52 week low of $21.74 and a 52 week high of $63.57.

10x Genomics (NASDAQ:TXGGet Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm had revenue of $141.01 million during the quarter, compared to analyst estimates of $142.24 million. During the same period last year, the firm posted ($0.44) EPS. 10x Genomics’s revenue was up 5.0% on a year-over-year basis. Equities research analysts anticipate that 10x Genomics, Inc. will post -1.55 EPS for the current year.

10x Genomics Profile

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGFree Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.